atai Life Sciences
 | |
| NASDAQ: ATAI | |
| Public | |
| ISIN | 🆔 |
| Industry | Healthcare |
| Founded 📆 | 2018 |
| Founder 👔 | |
| Headquarters 🏙️ | Berlin, Germany |
Area served 🗺️ | |
Key people | Christian Angermayer, Florian Brand, Lars Christian Wilde, Srinivas Rao |
| Members | |
Number of employees | |
| 🌐 Website | atai Life Sciences |
| 📇 Address | |
| 📞 telephone | |
Atai Life Sciences is a clinical-stage biopharmaceutical company that leverages alternative treatments for mental health disorders. Founded in 2018 and headquartered in Berlin, it has additional offices in New York and London. The company uses a decentralised, technology and data-driven platform model working with various psychedelic compounds such as Psilocybin, R-ketamine and Ibogaine to treat mental health disorders such as depression, anxiety, PTSD and addiction.
History[edit]
The company was founded in 2018 by Christian Angermayer, Florian Brand, Lars Christian Wilde, Srinivas Rao. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange[1].
Atai incorporates a model of developing some assets in house, its primarily employing a “buy and build” strategy where it acquires controlling stakes in early-stage companies. Thus far company has acquired 3 organisations, their most recent acquisition was Psyber on Apr 7, 2021.[2] These operate as subsidiaries with a shared operational backbone. The first of atai’s psychedelic programs was embodied in Compass Pathways (NASDAQ: CMPS), which conducted an IPO in September of 2020 was valued at over $1.3B as of November 2020.[3]
References[edit]
- ↑ Ponieman, Natan (14 June 2021). "Psyched: Atai's $214M IPO, MindMed CEO Resigns, Field Trip Applies To Nasdaq, Cybin And Novamind Target Frontline Health Workers". finance.yahoo.com. Retrieved 2021-06-24.
- ↑ Shead, Sam (9 April 2021). "Peter Thiel-backed firm takes majority stake in a brain computer interface start-up". CNBC. Retrieved 2021-06-19.
- ↑ Woolley, Suzanne (18 September 2020). "'Magic Mushroom' Company Goes Mainstream, Jumps 71% Post-IPO". www.bloomberg.com. Retrieved 2021-06-19.
This article "Atai Life Sciences" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Atai Life Sciences. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
